Peptide Initiative

Peptides · Peptide comparison

Adrenomedullin vs Thymosin Beta-4

A powerful vasodilatory peptide that relaxes blood vessels and helps your body maintain healthy fluid balance and blood pressure.

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeAdrenomedullin10–10 ng/kg/minThymosin Beta-42–5 mg
FrequencyAdrenomedullinOnce dailyThymosin Beta-4Twice weekly
AdministrationAdrenomedullinIntravenous infusionThymosin Beta-4Subcutaneous injection
Cycle lengthAdrenomedullinOngoing/indefiniteThymosin Beta-48-12 weeks
Onset speedAdrenomedullinModerate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelAdrenomedullinModerate human trials (Phase 1-2)Thymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Cardiovascular Support

Adrenomedullin82%
Thymosin Beta-4No recorded rating

Tissue Protection

Adrenomedullin78%
Thymosin Beta-4No recorded rating

Immune Function

Adrenomedullin74%
Thymosin Beta-4No recorded rating

Wound Healing

AdrenomedullinNo recorded rating
Thymosin Beta-495%

Inflammation Reduction

AdrenomedullinNo recorded rating
Thymosin Beta-488%

Tissue Regeneration

AdrenomedullinNo recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Adrenomedullin

Molecular formula
C264H406N80O77S3
Molecular weight
6029 Da (Daltons)
Half-life
Approximately 20-30 minutes in plasma (rapid metabolism)
Bioavailability
Parenteral administration only; peptide undergoes proteolytic cleavage in circulation
CAS number
148498-78-6

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Adrenomedullin

Intravenous

  • 5 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)Adrenomedullin is given as a slow drip into a vein in clinical trials, not by self-injection. This low dose was the bottom step tested for steroid-resistant ulcerative colitis. [4]
  • 10 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)Middle dose tested in the ulcerative colitis trial. [4]
  • 15 ng/kg/minContinuous infusion, 8 hours per day · 14 days (trial protocol)This higher dose was the only one that significantly improved disease scores in the trial. The same 15 ng/kg/min rate was also tested safely in healthy volunteers. [4][5]

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Adrenomedullin

Cardiovascular health optimization
Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Maintaining healthy blood pressure
Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from illness or sepsis
Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tissue protection and oxygen delivery
Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Adrenomedullin

Common

  • Mild discomfort at treatment site
  • Excessive blood pressure lowering (hypotension)
  • Headaches (from pressure changes)
  • Flushing and mild facial redness
  • Dizziness or lightheadedness
  • Mild electrolyte shifts
  • Localized injection site reactions
  • Increased urination (natriuretic effect)

Serious

  • Severe allergic reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Adrenomedullin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses.

Contraindications

  • Severe hypotension or shock states
  • Concurrent use with certain vasopressor medications
  • Pregnancy and breastfeeding
  • Severe kidney or liver dysfunction

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Adrenomedullin

Choose Adrenomedullin if…

  • Cardiovascular health optimization
  • Maintaining healthy blood pressure
  • Recovery from illness or sepsis
  • Tissue protection and oxygen delivery

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation